Trial · NCT03271021
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12. | FMX101, 4% Minocycline Foam | 16.39 | 95% Confidence Interval 15.53 to 17.25 | Lesion Count | |
| The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12. | Vehicle Foam | 12.74 | 95% Confidence Interval 11.88 to 13.61 | Lesion Count | |
Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline | FMX101, 4% Minocycline Foam | 199 | participants | ||
Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline | Vehicle Foam | 133 | participants | ||
| The Absolute Change From Baseline in the Non-inflammatory Lesion Count at Week 12 | FMX101, 4% Minocycline Foam | 18.80 | 95% Confidence Interval 17.06 to 20.54 | Lesion Count | |
| The Absolute Change From Baseline in the Non-inflammatory Lesion Count at Week 12 | Vehicle Foam | 15.89 | 95% Confidence Interval 14.14 to 17.65 | Lesion Count | |
| The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 9 | FMX101, 4% Minocycline Foam | 15.59 | 95% Confidence Interval 14.80 to 16.38 | Lesion Count | |
| The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 9 | Vehicle Foam | 11.72 | 95% Confidence Interval 10.92 to 12.52 | Lesion Count | |
| The Absolute Change From Baseline in the Inflammatory Lesion Count at the Interim Visit at Week 6 | FMX101, 4% Minocycline Foam | 13.09 | 95% Confidence Interval 12.29 to 13.89 | Lesion Count | |
| The Absolute Change From Baseline in the Inflammatory Lesion Count at the Interim Visit at Week 6 | Vehicle Foam | 9.57 | 95% Confidence Interval 8.76 to 110.37 | Lesion Count | |
| IGA Treatment Success (Dichotomized as Yes/no) at Week 6, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 6 | FMX101, 4% Minocycline Foam | 84 | participants | ||
| IGA Treatment Success (Dichotomized as Yes/no) at Week 6, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 6 | Vehicle Foam | 46 | participants | ||
| IGA Treatment Success (Dichotomized as Yes/no) at Week 9, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 9 | FMX101, 4% Minocycline Foam | 137 | participants | ||
| IGA Treatment Success (Dichotomized as Yes/no) at Week 9, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 9 | Vehicle Foam | 79 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03271021/results